Evidence map›Paper›PMID 26208475›Full record

ArticleWiener medizinische Wochenschrift (1946)2015

Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.

Julian Ananiev, Elina Aleksandrova, Desislava Skerleva, Maya Gulubova, Anastasiya Chokoeva, Torello Lotti, Uwe Wollina, Georgi Tchernev, Milica Kontić, Jelena Stojšić

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. The Effect ofJournal of Cancer · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Julian AnanievDepartment of General and Clinical Pathology, Medical Faculty, Trakia University, Armeiska str.11, 6000, Stara Zagora, Bulgaria, julian.r.ananiev@gmail.com.
Elina Aleksandrova
Desislava Skerleva
Maya Gulubova
Anastasiya Chokoeva
Torello Lotti
Uwe Wollina
Georgi Tchernev
Milica Kontić
Jelena Stojšić
Trakia University · BGMilitary Medical Academy · BGKrankenhaus Dresden-Friedrichstadt · DEMarconi University · ITMinistry of Interior · BGUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to assess the expression and significance of HER2 and HER3, and Ile/Val single nucleotide polymorphism (SNP) of HER2 in lung cancer patients. Thirty seven cases of lung cancer were investigated immunohistochemically for HER2 and HER3 expression. PCR followed by restriction fragment length polymorphism (RFLP) was used to analyze the presence of HER-2 SNP at codon 655 in 20 samples. The results were compared with clinical and pathological parameters of investigated patients.We found that 100% of the cases were negative for HER2, 29.7% were with moderate or strong HER3 expression and 70.3% of the tumors-without or with low expression for HER3. Lymph node metastasis were found in 40% of HER3 positive cases (χ(2) = 4.752; p = 0.029). Moderately-differentiated tumors do not express neither of investigated markers (χ(2) = 6.719; p = 0.035). HER2 RFLP-PCR analysis showed genotype AG in five patients (25%) and the rest of 15 cases (75%) had АА (Ile/Ile) genotype. Patients with metastasis had genotype АА (Ile/Ile) in 80% and genotype AG (Ile/Val) in 20% (χ(2) = 2.857; p = 0.091).Our results indicate that SNP in HER2 codon 655 and investigation of HER2 and HER3 expression could be helpful to outline the prognosis for patients with lung adenocarcinoma.

Indexed as

AdenocarcinomaAgedCodonErb-b2 Receptor Tyrosine KinasesFemaleGene Expression RegulationHumansIsoleucineLung NeoplasmsMaleMiddle AgedNeoplasm StagingPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single NucleotidePrognosisCodonERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanIsoleucineReceptor, ErbB-3Valine

Identifiers

PMID26208475
OpenAlexW1002862203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.